Wall Street Analysts Are Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on MacroGenics (MGNXResearch Report) and Stemline Therapeutics Inc (STMLResearch Report) with bullish sentiments.

MacroGenics (MGNX)

In a report released today, Debjit Chattopadhyay from H.C. Wainwright maintained a Buy rating on MacroGenics, with a price target of $18.00. The company’s shares closed last Monday at $9.97, close to its 52-week low of $9.33.

According to TipRanks.com, Chattopadhyay has 0 stars on 0-5 star ranking scale with an average return of -11.4% and a 32.6% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Precision BioSciences Inc, and Voyager Therapeutics Inc.

Currently, the analyst consensus on MacroGenics is a Strong Buy with an average price target of $25.00, which is a 150.0% upside from current levels. In a report released today, Wedbush also maintained a Buy rating on the stock with a $14.00 price target.

See today’s analyst top recommended stocks >>

Stemline Therapeutics Inc (STML)

Cowen & Co. analyst Boris Peaker maintained a Buy rating on Stemline Therapeutics Inc today. The company’s shares closed last Monday at $9.40, close to its 52-week low of $7.82.

According to TipRanks.com, Peaker is ranked 0 out of 5 stars with an average return of -2.8% and a 38.0% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Mersana Therapeutics Inc, and Molecular Templates Inc.

Currently, the analyst consensus on Stemline Therapeutics Inc is a Strong Buy with an average price target of $27.25.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.